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http://dx.doi.org/10The critical human cells that produce neutrophils and platelets within 3 weeks in recipi-
ents of hematopoietic transplants are thought to produce these mature blood cells with
the same kinetics in sublethally irradiated immunodeficient mice. Quantification of their
numbers indicates their relative underrepresentation in cord blood (CB), likely explaining
the clinical inadequacy of single CB units in rescuing hematopoiesis in myelosuppressed
adult patients. We here describe that exposure of CD34+ CB cells ex vivo to growth
factors that markedly expand their numbers and colony-forming cell content also rapidly
(within 24 hours) produce a significant and sustained net loss of their original short-term
repopulating activity. This loss of short-term in vivo repopulating activity affects early
platelet production faster than early neutrophil output, consistent with their origin from
distinct input populations. Moreover, this growth factor-mediated loss is not abrogated
by published strategies to increase progenitor homing despite evidence that the effect on
rapid neutrophil production is paralleled in time and amount by a loss of the homing of
their committed clonogenic precursors to the bone marrow. These results highlight the
inability of in vitro or phenotype assessments to reliably predict clinical engraftment
kinetics of cultured CB cells. Copyright  2016 ISEH - International Society for Exper-
imental Hematology. Published by Elsevier Inc. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Transplantation of hematopoietic cells is a critical compo-
nent of treatments that cure many life-threatening hemato-
logic disorders. Cells with long-term repopulating activity
are essential for durable recovery and gene therapy applica-
tions, but are not the main source of early-appearing neutro-
phils and platelets produced by most transplants [1–3].
Rather, prevailing evidence indicates that these critical
early outputs of mature blood cells derive from typically
more prevalent cells with an immediate, but also self-
limited and lineage-restricted capacity for producing spe-
cific types of mature blood cells [4–7].
Growth factors (GFs) regulate primitive hematopoietic
cell survival, proliferation, and differentiation [8] and can
also influence their adherence to bone marrow (BM)
microenvironment elements [9]. Initially, GFs anticipated
to be useful for the generation of cells ex vivo for use in: Connie J. Eaves, Terry Fox Laboratory, 675 West
er, BC V5Z 1L3, Canada; E-mail: ceaves@bccrc.ca
 2016 ISEH - International Society for Experimental Hem
se (http://creativecommons.org/licenses/by-nc-nd/4.0/).
.1016/j.exphem.2016.04.003clinical transplants were identified by their ability to stim-
ulate the production of progenitors identified in vitro as
colony-forming cells (CFCs) or separately detected pre-
cursors of these cells [10,11]. Many studies have also
examined the types and concentrations of GFs required
to expand human cell populations containing cells with
long-term output activities [11–17]. However, stringent
assessment of these conditions using currently available
immunodeficient mice indicates that additional supple-
ments are required [18,19]. Importantly, others have re-
ported that a prolonged exposure of human
hematopoietic cells to GFs in vitro can have a detrimental
effect on the level of human chimerism obtained in trans-
planted mice 6–10 weeks later [20–22], some of which
may be attributed to a transient loss of repopulating activ-
ity that occurs when the injected cells are in S/G2/M
phases of the cell cycle [14]. However, a quantitative anal-
ysis of effects of GF exposure on human cells with short-
term repopulating activity in vivo (so-called STRCs) has
not been reported. This situation is notable as significantatology. Published by Elsevier Inc. This is an open access article under the
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culture-expanded cells have yet to be achieved.
We now describe how multiple GFs produce a profound,
rapidly initiated and sustained net loss of STRC activity in
ex vivo exposed CD34þ CB cells that correlates with a loss
in efficiency of progenitor homing to the bone marrow.
These results caution against the reliance on either
in vitro or phenotype assessments to predict clinical
engraftment kinetics of cultured hematopoietic cells.Figure 1. Experimental outline. CD34þ CB cells were quantified, either
directly or after being cultured for varying periods in the presence of
various GFs, for CFC numbers, for their ability to home to the BM of
transplanted immunodeficient mice, or after 3 weeks to produce human
GM cells and platelets that appear in the peripheral blood of these recip-
ients. 3GS 5 mice transgenic for human IL-3/GM-CSF/SCF.Methods
Human cells
CD34þ-enriched (O80%) suspensions of pooled human cord
blood (CB) cells were obtained using an EasySep kit (STEM-
CELL Technologies, Vancouver, BC, Canada) from cryopreserved
collections according to procedures approved by the University of
British Columbia Research ethics board.
Cell cultures
Suspension cultures of CD34þ cells were initiated with 105 cells/
mL in a serum-free medium (SFM) consisting of Iscove’s modi-
fied Dulbecco’s medium (IMDM) containing 10 mg/mL bovine
serum albumin, 10 mg/mL bovine pancreatic insulin, and
200 mg/mL human iron-saturated transferrin (BIT, STEMCELL
Technologies), 40 mg/mL low-density lipoproteins (STEMCELL
Technologies), 2 mmol/L glutamine (STEMCELL Technologies),
and 104 mol/L b-mercaptoethanol (Sigma-Aldrich, Oakville,
ON, Canada), in non-tissue culture-treated plates. The GFs added
were 100 ng/mL FLT3 ligand (FLT3L, Amgen, Thousand Oaks,
CA), 100 ng/mL stem cell factor (SCF), 20 ng/mL granulocyte
colony-stimulating factor (GCSF, STEMCELL Technologies),
20 ng/mL interleukin (IL)-3 (Novartis, Basel, Switzerland), and
20 ng/mL IL-6 (Cangene, Winnipeg, MB, Canada) (5-GF cock-
tail), or 100 ng/mL FLT3L, 100 ng/mL SCF, and 50 ng/mL throm-
bopoietin (TPO, STEMCELL Technologies) (3-GF cocktail).
Additional medium was added every 2 to 3 days to maintain a
cell density less than 106 cells/mL. Prior to treatment with
16,16-dimethyl prostaglandin E2 (PGE2, Cayman Chemical,
Ann Arbor, MI) and diprotin A (Sigma-Aldrich), cells were
washed, resuspended in freshly prepared SFM þ 5-GF cocktail,
and transferred to new culture wells. CFC assays were performed
as described [23].
Transplantation procedures
Cells were injected intravenously into 8- to 12-week-old NOD-
scid-Il2rgcnull (NSG) mice or NSG mice engineered transgeni-
cally to express human IL-3, human granulocyte–macrophage
(GM)-CSF, and human SCF (NSG-3GS mice) irradiated with
315 cGy 137Cs g rays. STRC activity was determined on
antibody-stained blood samples obtained 3 weeks later. Effects
on BM CFC homing were assessed by injecting 5  104 CD34þ
CB cells, or their cultured derivatives, into mice and comparing
the proportions of CFCs detected in assays of cells recovered
16 hours posttransplant from two femurs of recipients of control
versus test cells. Mice were maintained under specific pathogen-
free conditions using protocols approved by the Animal Care
Committee of the University of British Columbia.Flow cytometry
Absolute numbers of human CD34þ cells, human CD45þCD33/
15þ GMs, and FSClowCD41þCD61þ platelets were determined
using appropriate antibodies and AccuCheck counting beads
(Life Technologies) [5,24].
Statistical analysis
Data are geometric means 6 SEM. Differences were examined in
R Version 3.2.3 [25] using the Student t test.Results
CD34þ CB cells cultured for 7 days with a 5-GF cocktail
(Fig. 1) exhibited expected increases [11] in CD34þ cells
and CFCs (six- and twelvefold, respectively) (Fig. 2A). In
contrast, NSG-3GS mice transplanted intravenously with
aliquots of the same cells exhibited a tenfold net reduction
in STRC activity relative to the freshly isolated CD34þ
cells (Fig. 2B). Similar results were obtained for cells
cultured for 12 days in 3-GF cocktail (Fig. 2B). In addition,
we found that the consistent marked loss of in vivo STRC
activity that occurred in these cultures was not affected
by including 35 nmol/L UM171 [19] (STEMCELL Tech-
nologies) in the medium nor by exposing the cultured cells
for 2 hours to 10 mmol/L 16,16-dimethylprostaglandin E2
(PGE2, Cayman Chemical, Ann Arbor, MI) [26] plus
5 mmol/L diprotin A (Sigma-Aldrich) added in the last
15 min [27] just before their transplantation into mice
(Fig. 2B).
Figure 2. Cultured CD34þ CB cells exhibit profound and selective loss of
STRC activity. (A) Increase in CD34þ cell (left panel) and CFC (right
panel) numbers after 7 days of culture of CD34þ CB cells in SFM þ
5-GF cocktail (four experiments). (B) Levels of human GM cells and plate-
lets in the peripheral blood of NSG-3GS mice transplanted 3 weeks before
with the progeny of 104 CD34þ CB cells (‘‘input’’) cultured for 7 days in
SFM þ 5-GF cocktail (9 mice) or SFM þ 5-GF
cocktail þ PGE2 þ diprotin A (3 mice), or for 12 days in SFM þ 3-GF
cocktail (10 mice) or SFM þ 3-GF cocktail þ UM171 (10 mice), ex-
pressed as percentages of the corresponding levels obtained from the cells
used to initiate the cultures (20 mice). The upper horizontal dotted line and
gray bar indicate the mean and range defined by 61 SEM, respectively, of
pooled values obtained with the input cells. The lower dotted line indicates
the platelet detection threshold. Asterisks indicate statistically significant
differences (***p # 0.001) between each condition and the freshly iso-
lated control.
Figure 3. Growth factor-induced loss of STRC activity occurs rapidly. Ki-
netics of the culture-induced loss of human GM (A) and platelet (B) STRC
activity assessed 3 weeks posttransplant (2  104 CD34þ cells injected per
NSG-3GS mouse, 8 mice per point). Effect on human GM (C) and platelet
(D) STRC activity of culturing 2  104 CD34þ CB cells for 24 hours in
SFM only (10 mice), low-insulin SFM only (6 mice), IMDM þ 2% FBS
(11 mice), SFM þ IL-3 (7 mice), SFM þ GCSF þ IL-6 (5 mice),
SFM þ SCF þ FLT3L (7 mice), or SFM þ SCF þ FLT3L þ TPO (8
mice). Values shown are the chimerism levels in NSG-3GS mice obtained
by the cultured transplants, expressed as a percentage of the chimerism
levels obtained from the number of precultured cells (‘‘input’’) used to
derive the same number of cultured cells tested (20 mice). The 1/200 insu-
lin level (5 60 ng/mL) is 1/200th of the concentration of insulin in stan-
dard SFM. The horizontal dotted line and gray bar, respectively,
indicate the mean and range defined by61 SEM of pooled values obtained
with the input cells. Asterisks indicate statistically significant differences
(
B
p # 0.10, **p # 0.01, ***p # 0.001) between each condition and the
freshly isolated control value. ND 5 not detected.
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relation to when the cells begin to divide, we next under-
took a series of time course experiments. The results indi-
cated that both GM (Fig. 3A) and platelet (Fig. 3B)
STRC activities were reduced below input values within
24 hours, with CFC numbers remaining unchanged
(270 6 30 vs. 250 6 40 colonies per 103 initial CD34þ
CB cells, four experiments). Interestingly, these experi-
ments also indicated that the 3-week platelet output activitywas already maximally reduced after 4 hours of GF expo-
sure, whereas a detectable effect on GM output activity
was not seen until after 24 hours.
We next designed a series of experiments to assess the
potential contributions of the different components of the
medium in which the CD34þ CB cells were being cultured.
Overall the results indicated that most of the GFs tested
alone (IL-3) or as ‘‘like’’ pairs (GCSF þ IL-6,
638 P.H. Miller et al./ Experimental Hematology 2016;44:635–640SCF þ FLT3L) significantly reduced both types of STRC
activity within 24 hours, although often less markedly
than consistently obtained with the 5-GF cocktail
(Fig. 3C and D). Conversely, removal of all GFs appeared
to have little effect on STRC activity that would not have
been explained by a parallel loss of viability (in either stan-
dard SFM or SFM containing 0.5% of the standard concen-
tration of insulin, to match the molar concentrations of the
other GFs) and could be variably rescued by the addition of
2% fetal bovine serum (FBS, STEMCELLTechnologies) to
the SFM. Interestingly, replacement of the 5-GF cocktail
with the 3-GF cocktail also did not result in a loss of either
GM or platelet STRC activity within the first 24 hours of
culture (Fig. 3C and D) despite the significant net loss after
12 days (Fig. 2B).
We then investigated whether the rapid loss of STRC ac-
tivity might be caused by a reduction in the ability of the
STRCs to home to the BM. Because STRCs have not
been purified and their detection requires an ability to
home to BM, we assessed CFC homing as a surrogate.
These experiments revealed that the proportion of CFCs
harvested from 24-hour cultures that homed to the BMFigure 4. Growth factor culture is associated with a reduction in effi-
ciency of CFC homing to the BM. Effect on BM homing activity of
CFCs cultured for 24 hours in SFM þ 5-GF cocktail (7 mice),
SFM þ 3-GF cocktail (6 mice), or IMDM þ 2% FBS (6 mice), tested
in NSG-3GS (solid circles) or NSG (open circles) recipients. Values shown
are the proportions of CFCs detected in pooled cells from two femurs
16 hours after intravenous injection of the cultured cells, expressed as a
percentage of the proportion of CFCs in pooled cells from two femurs
16 hours after intravenous injection of the precultured cells (‘‘input,’’ 12
mice). The horizontal dotted line and gray bar indicate the mean and range
defined by 61 SEM, respectively, of pooled values obtained with the input
cells. Asterisks indicate statistically significant differences (*p # 0.05,
***p # 0.001) between each condition and the freshly isolated control
value.was reduced threefold by comparison to the CFCs in the
freshly isolated CD34þ CB cells (Fig. 4), despite the lack
of any change in CFC numbers during the 24-hour culture
period. When the cells were cultured in the 3-GF cocktail
for 24 hours, the proportion of CFCs that homed to the
BM was reduced by only 20%, mirroring the lack of effect
on STRC activity in this shorter time frame (Fig. 3C and
D). Similar parallelism between retained CFC homing
and STRC activity was observed when the homing assay
was applied to cells cultured in SFM plus 2% FBS, but
no GFs (Fig. 4).Discussion
To date no phenotype or in vitro assay has proven to be a
reliable predictor of the rapidity with which neutrophils or
platelets will appear in the blood of patients transplanted
with cultured hematopoietic cells. Indeed, there is little
information regarding the ability of GFs alone to support
the robust expansion of human hematopoietic cells
capable of producing large numbers of neutrophils and
platelets early after transplant. We have now described
the rapidity with which multiple GFs, alone or even
more markedly in combination, appear to selectively
impair the ability of primitive human hematopoietic cells
to subsequently regenerate mature neutrophils and plate-
lets within 3 weeks in transplanted immunodeficient re-
cipients, but without inducing evidence of any loss of
CD34þ cells or CFCs. This finding and the similarity in
speed and magnitude of the GF-induced homing defi-
ciency of CFCs suggest that an initial homing failure,
rather than a loss of viability or differentiation capacity,
is responsible for the subsequent deficient in vivo outputs
of neutrophils (and platelets). The differential effect on
the cells responsible for producing these different outputs
[5] highlights a potential need for cell-specific culture
conditions to preserve their different in vivo differentia-
tion activities.
A similar phenomenon has been reported in long-term
repopulating cells of both human and mouse, with a loss
of activity when cells are in the S/G2/M cell cycle phase.
However, these reports also indicated that these effects
are restricted to these cells and do not similarly affect
proliferating shorter-term repopulating cells [14,28–30].
Thus, multiple mechanisms appear to determine the
engraftment capacity of cells with variable innate reconsti-
tuting potential.
Here we also reported that exposure to GFs, rather than
the physical act of being incubated ex vivo, leads to an im-
mediate loss of the transplantability of cells that can pro-
duce mature neutrophils and platelets within 3 weeks
in vivo. This suggests that efforts to improve cell expansion
systems will require that serious attention be given to
reducing the negative effects of GFs on these cells, rather
than simply adding agents anticipated to elicit novel growth
639P.H. Miller et al./ Experimental Hematology 2016;44:635–640responses of more primitive cells. However, the solution
will also need to consider the important anti-apoptotic ef-
fects of GFs on these same STRCs, which here could be
partially abrogated by replacing the GF supplement with
2% FBS, but not with any single GF thus far tested.
In summary, ex vivo GF exposure can rapidly induce a
loss of in vivo STRC activity, and these effects are corre-
lated with a loss of efficiency of progenitor homing to the
BM. These results have implications for strategies designed
to expand long-term repopulating cells ex vivo that also
require preservation of cells able to produce neutrophils
and platelets early posttransplant.Acknowledgments
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